RT Journal Article
SR Electronic
T1 International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 915
OP 924
DO 10.1097/IGC.0000000000001263
VO 28
IS 5
A1 Jennifer J. Mueller
A1 Henrik Lajer
A1 Berit Jul Mosgaard
A1 Slim Bach Hamba
A1 Philippe Morice
A1 Sebastien Gouy
A1 Yaser Hussein
A1 Robert A. Soslow
A1 Brooke A. Schlappe
A1 Qin C. Zhou
A1 Alexia Iasonos
A1 Claus Høgdall
A1 Alexandra Leary
A1 Roisin E. O’Cearbhaill
A1 Nadeem R. Abu-Rustum
YR 2018
UL http://ijgc.bmj.com/content/28/5/915.abstract
AB Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes.Methods This was a retrospective review spanning 1976–2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed.Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy—55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%–85%) for patients with stage I to II disease and 17% (95% CI, 8%–29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%–86%) for patients who underwent fertility-preserving surgery.Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.